Literature DB >> 3874110

Fecal alpha 1-antitrypsin measurement: an indicator of Crohn's disease activity.

S Meyers, A Wolke, S P Field, E J Feuer, J W Johnson, H D Janowitz.   

Abstract

Random fecal alpha 1-antitrypsin levels were determined in 34 patients, 24 with Crohn's disease, and 10 "controls" having diarrheal illnesses not associated with intestinal protein loss, in an effort to evaluate its usefulness as a measure of Crohn's disease intestinal activity. In the control group, all alpha 1-antitrypsin levels were less than 2 mg/g dry wt of stool. The mean fecal level among those with Crohn's disease was 52.9 mg/g (range less than 2 to greater than or equal to 200). There was a strong correlation between disease activity, as measured by a clinical score, and the alpha 1-antitrypsin levels (Spearman r = 0.65, p = 0.001). This correlation was similarly strong among those with colitis or ileitis. A fecal value greater than 20 mg/g may provide a rough guideline to separate patients with clinically active disease from those with inactive Crohn's disease, despite a considerable range of fecal levels among patients with a particular clinical score. Fecal alpha 1-antitrypsin levels correlated with several other laboratory measures that have been proposed as indicators of Crohn's disease activity. The serum orosomucoid, C-reactive protein, and albumin correlated with the clinical activity score among some of our patient groups. Both clinical scores and laboratory parameters, however, may have limited usefulness in a variety of circumstances. Random fecal alpha 1-antitrypsin determinations seem to provide a reliable, although not directly quantitative, measure of the intestinal activity among patients with Crohn's disease, especially when other methods may be inconclusive.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3874110     DOI: 10.1016/0016-5085(85)90739-5

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

1.  Structural heterogeneity of faecal alpha 1 antitrypsin shown by immunoblot analysis in patients with Crohn's disease.

Authors:  F Boege; W Fischbach
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

Review 2.  Non-invasive investigation of inflammatory bowel disease.

Authors:  J A Tibble; I Bjarnason
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

3.  Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls.

Authors:  S C Bischoff; J Grabowsky; M P Manns
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

4.  Qualitative differences in faecal alpha-1-antitrypsin in patients with Crohn's disease.

Authors:  J F Colombel; C Mizon; M Balduyck; A Cortot
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

5.  Faecal alpha-1-antitrypsin in chronic inflammatory bowel disease.

Authors:  D W Thomas
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

6.  Predicting relapses of Crohn's disease. Clouds in the crystal ball.

Authors:  D B Sachar
Journal:  Dig Dis Sci       Date:  1987-02       Impact factor: 3.199

Review 7.  Laboratory assessment of inflammatory bowel disease.

Authors:  I T Beck
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

8.  Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  C Cellier; T Sahmoud; E Froguel; A Adenis; J Belaiche; J F Bretagne; C Florent; M Bouvry; J Y Mary; R Modigliani
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

Review 9.  Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases.

Authors:  Jason Orlando Dimitri Musci; Jack Stephen Cornish; Jan Däbritz
Journal:  J Gastroenterol       Date:  2016-03-14       Impact factor: 7.527

10.  Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases.

Authors:  W Fischbach; W Becker; J Mössner; W Koch; C Reiners
Journal:  Gut       Date:  1987-04       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.